Charles River Laboratories International, Inc. (CRL) is listed on NYSE in Healthcare Services Stocks. It is $291.49, -1.66%, with a $13.9B market cap. RSI is 69.9, near overbought. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 69.9 Near Overbought
Market Cap $13.9B
Volume 421.0K
Fundamentals — 10-Q Q2 2026
Revenue $2.0B
Net Income $-16.3M
EPS $-0.34
Operating Margin 12.0%
Net Margin -0.8%
P/E Ratio -857.3x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Foster James C | Director | Sell | 33,561 | $300.00 | $10.1M | 2026 Aug 25 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Sell | 2,039 | $294.12 | $599,711 | 2026 Aug 19 |
| Andrews Nancy C | Director | Sell | 573 | $285.24 | $163,443 | 2026 Aug 18 |
| Girshick Birgit | Chief Executive Officer | Sell | 6,500 | $279.90 | $1.8M | 2026 Aug 11 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Sell | 3,714 | $279.66 | $1.0M | 2026 Aug 11 |
| Foster James C | Director | Sell | 28,733 | $275.00 | $7.9M | 2026 Aug 10 |
| Knell Michael Gunnar | SVP, Finance and CAO | Sell | 6,645 | $260.38 | $1.7M | 2026 Aug 6 |
| Creamer Victoria L | EVP & Chief People Officer | Sell | 4,179 | $259.16 | $1.1M | 2026 Aug 6 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Sell | 5,046 | $263.00 | $1.3M | 2026 Aug 5 |
| Foster James C | Director | Sell | 75,000 | $225.00 | $16.9M | 2026 Jun 29 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop | Buy | 25 | $174.54 | $4,364 | 2026 Mar 3 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop | Sell | 800 | $157.60 | $126,080 | 2025 Aug 18 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop | Sell | 400 | $150.04 | $60,016 | 2025 Aug 7 |
| Massaro George | Director | Sell | 140 | $137.57 | $19,260 | 2025 May 15 |
| Massaro George | Director | Sell | 140 | $140.73 | $19,703 | 2025 May 14 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop | Sell | 500 | $145.41 | $72,705 | 2025 May 13 |
| Foster James C | Chairman, President and CEO | Buy | 6,075 | $165.01 | $1.0M | 2025 Feb 20 |
| Girshick Birgit | Corporate Executive VP & COO | Buy | 1,514 | $164.63 | $249,250 | 2025 Feb 20 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop | Sell | 4,400 | $162.50 | $715,000 | 2025 Feb 20 |
| Wallman Richard F | Director | Sell | 7,621 | $216.17 | $1.6M | 2024 Nov 7 |
Other Healthcare Services Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $894.35 | 58.3 | $104.3B |
| | $417.60 | 60.5 | $92.6B |
| | $321.94 | 56.1 | $61.4B |
| | $161.72 | 51.9 | $21.7B |
| | $28.84 | 44.7 | $6.6B |
| | $234.57 | 53.8 | $54.6B |
| | $25.64 | 67.5 | $7.2B |
| | $326.17 | 62.5 | $47.0B |
Take CRL further
- Browse Healthcare Services Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put CRL in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Charles River Laboratories International, Inc. next reports.
Set alerts on CRL
Get notified when Charles River Laboratories International, Inc. hits your price targets or technical conditions are met.
Get Started Free